Kevin is the interim president of Editas Medicine and a principal at Polaris Partners. He joined Polaris in 2004 and focuses on investments in health care. Kevin is a co-founder of Genocea Biosciences and Sirtris Pharmaceuticals (acquired by GSK) and was the founding CEO at Visterra Inc. (formerly Parasol Therapeutics).
He currently represents Polaris as a director of InSeal Medical, Genocea Biosciences, Kala Pharmaceuticals, Neuronetics, Inc., Visterra Inc., Taris Biomedical and Vets First Choice. Additionally, he is a board observer to Arsenal Medical and 480 Biomedical.Kevin holds a Ph.D. in genetics from Harvard Medical School. His doctoral research focused on the molecular regulation of caloric restriction and on modulation of a novel class of protein deacetylases.
Jun, 2017 - Current (3 months)
|Dec 22, 2016||Med City News - MedCity INVEST and Alice’s adventures in wonderland|
|Jun 30, 2016||Business Wire - Morphic Therapeutic Announces $51.5 Million Series A Financing to Develop Next-Generation Integrin Therapies|
|Jan 28, 2016||WSJ Blogs - Biotech Venture Investors Expect Slowdown Despite Record 2015|
|Oct 27, 2015||Venture Beat - TARIS Biomedical® Raises $32 Million and Expands Leadership Team and Board of Directors|
|Oct 27, 2015||Xconomy - Taris 2.0: A Year After Buyout, VCs Bet $32M More on a Second Strike|
|Oct 27, 2015||Business Wire - TARIS Biomedical® Raises $32 Million and Expands Leadership Team and Board of Directors|
|Oct 27, 2015||PE HUB - TARIS Biomedical scores $32 mln|
|Oct 5, 2015||MaineBiz - Benjamin Shaw's Vets First Choice bites into traditional distribution|